Clinical Trials
34 trialsAB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
Jonsson Comprehensive Cancer Center
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20 Therapeutics
EYE/SPY
Société Française d'Endoscopie Digestive
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
Sir Run Run Shaw Hospital
TCR1188-ABC Cells in KRAS-mutated Cancers
University of Pennsylvania
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Tongji Hospital
SMART-B
Hospital de Clinicas de Porto Alegre
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
InnoPharmax Inc.
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
Virogin Biotech Ltd.
The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
Sir Run Run Shaw Hospital
ETCABIO
University Hospital, Angers
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
TransThera Sciences (Nanjing), Inc.
Adjuvant Chemotherapy for BTC Based on 3D-PTA
Fudan University
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
Shanghai Zhongshan Hospital
PEHRICCA
Federation Francophone de Cancerologie Digestive
Opti-LAMS
Waikato Hospital
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
3D Medicines
SED-RO-ICC
Shanghai Zhongshan Hospital
NEODISCO
Amsterdam UMC, location VUmc
TisGCS for BTC
National Cheng-Kung University Hospital
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Harbin Medical University
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
Third Affiliated Hospital, Sun Yat-Sen University
EMPHATIC
The Christie NHS Foundation Trust
LIVINCA
Jena University Hospital
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
CVL009-C2001
Convalife (Shanghai) Co., Ltd.
Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin
Chang Gung Memorial Hospital
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Tianjin Medical University Cancer Institute and Hospital
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma
Fudan University
ACTICCA-2
Universitätsklinikum Hamburg-Eppendorf
Neoadjuvant PDT in the Treatment of Cholangiocarcinoma
First Affiliated Hospital Xi'an Jiaotong University